Akebia Therapeutics (AKBA) Payables (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Payables data on file, last reported at $8.4 million in Q1 2026.

• Payables for Q1 2026 came in at $8.4 million, down 33.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (down 33.75% YoY), and the FY2025 annual result was $21.2 million, up 39.56% from the prior year.
• Payables fell to $8.4 million in Q1 2026 per AKBA's latest filing, from $21.2 million in the prior quarter.
• Over five years, Payables peaked at $24.9 million in Q2 2022 and troughed at $8.4 million in Q1 2026.
• A 5-year average of $14.4 million and a median of $12.7 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2024: Payables tumbled 54.14% in 2023, then surged 49.3% in 2024.
• A 5-year view of Payables shows it stood at $18.0 million in 2022, then declined by 18.79% to $14.6 million in 2023, then advanced by 3.72% to $15.2 million in 2024, then surged by 39.56% to $21.2 million in 2025, then tumbled by 60.42% to $8.4 million in 2026.
• Business Quant data shows AKBA's Payables at $8.4 million in Q1 2026, $21.2 million in Q4 2025, and $10.1 million in Q3 2025.